Christopher R. Apostol
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Christopher R. Apostol has a total of 15 co-authors. Here are the top co-authors by number of shared publications:
- Robin Polt
Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA
3 shared publications - John Michael Streicher
Department of Pharmacology, College of Medicine, University of Arizona
2 shared publications - Lajos Szabo
Department of Chemistry & Biochemistry, The University of Arizona, Tucson, AZ 85721, USA
2 shared publications - Chenxi Liu
University of Toronto Toronto Canada
1 shared publication - Daniel Varela
Facultat de Quìmica Tarragona, Universitat Rovera I Virgili, 43007 Barcelona, Spain
1 shared publication - Gabriella Molnar
Department of Pharmacology, University of Arizona, Tucson, AZ 85724, USA
1 shared publication
Latest Publications
- Open Access
Synthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAP1–23
The search for efficacious treatment of neurodegenerative and progressive neuroinflammatory diseases continues, as current therapies are unable to halt or reverse disease progression. PACAP represents one potential therapeutic that provides neuroprotection effects on neurons, and also modulates inflammatory responses and circulation within the brain. However, PACAP is a relatively long peptide hormone that is not trivial to synthesize. Based on previous observations that the shortened isoform PACAP1–23 is capable of inducing neuroprotection in vitro, we were inspired to synthesize shortened glycopeptide analogues of PACAP1–23. Herein, we report the synthesis and in vitro characterization of glycosylated PACAP1–23 analogues that interact strongly with the PAC1 and VPAC1 receptors, while showing reduced activity at the VPAC2 receptor.
Open AccessSynthesis and In Vitro Characterization of Glycopeptide Drug Candidates Related to PACAP1–23
The search for efficacious treatment of neurodegenerative and progressive neuroinflammatory diseases continues, as current therapies are unable to halt or reverse disease progression. PACAP represents one potential therapeutic that provides neuroprotection effects on neurons, and also modulates inflammatory responses and circulation within the brain. However, PACAP is a relatively long peptide hormone that is not trivial to synthesize. Based on previous observations that the shortened isoform PACAP1–23 is capable of inducing neuroprotection in vitro, we were inspired to synthesize shortened glycopeptide analogues of PACAP1–23. Herein, we report the synthesis and in vitro characterization of glycosylated PACAP1–23 analogues that interact strongly with the PAC1 and VPAC1 receptors, while showing reduced activity at the VPAC2 receptor.
- Open Access
- 14 September 2020
- Published by American Chemical Society (ACS)
Glycosylated PACAP hormones as potential therapy for Parkinsonism, stroke and traumatic brain injury
- 14 September 2020
- Published by American Chemical Society (ACS)
Open AccessGlycosylated PACAP hormones as potential therapy for Parkinsonism, stroke and traumatic brain injury